Target intelligence / Profile preview

Sodium-coupled neutral amino acid transporter 4 (SLC38A4)

Target
SLC38A4
Molecular classification
Transporter, Solute carrier family protein, System A/N amino acid transporter
01

Overview

Sodium-coupled neutral amino acid transporter 4 (SLC38A4) is a membrane transporter protein that mediates electrogenic symport of neutral amino acids and sodium ions across the cell membrane, primarily in the liver, placenta, and other tissues including kidney, muscle, and pancreas[1][3][5][7][10]. SLC38A4 has broad substrate specificity, favoring small neutral amino acids such as alanine, glycine, serine, asparagine, threonine, and glutamine, and also can transport cationic amino acids (e.g., arginine, lysine) by a Na(+)-independent mechanism[1][3][7][10]. It belongs to the solute carrier family (SLC), specifically family 38, and functions as both a system A and system N amino acid transporter, essential for maintaining amino acid homeostasis during cell growth, development, and metabolism[1][3][10]. SLC38A4 mutations have been linked to Mahvash Disease and abnormal fetal circulation; research suggests its key role in placental amino acid supply and metabolic adaptation during pregnancy[3][7].

Other names
ATA3NAT3PAATSNAT4Amino acid transporter A3Na(+)-coupled neutral amino acid transporter 4Solute carrier family 38 member 4System A amino acid transporter 3System N amino acid transporter 3
02

Mechanism of action

Not applicable; no approved drugs or investigational agents specifically targeting SLC38A4 are documented in search results.

03

Biological functions

Amino acid transmembrane transportSodium-dependent symport of neutral amino acidsCationic amino acid transport (Na+ and pH-independent)Regulator of amino acid homeostasis
04

Disease associations

Mahvash DiseasePersistent Fetal Circulation SyndromeOther roles under investigation; links to organ growth, metabolic regulation, development
05

Safety considerations

No specific safety concerns identified; potential risks may emerge if modulating essential amino acid transport in liver, embryo, or placenta
06

Interacting drugs

No clinically approved drugs reported to directly target SLC38A4 as of September 2025.
07

Biomarkers

None established for patient selection or efficacy monitoring in available sources.

Beyond the preview

Go deeper on Sodium-coupled neutral amino acid transporter 4 (SLC38A4).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sodium-coupled neutral amino acid transporter 4 (SLC38A4).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call